Alnylam Pharmaceuticals Inc. (ALNY)

73.02
1.52 2.13
NASDAQ : Health Technology
Prev Close 71.50
Open 72.54
Day Low/High 71.94 / 74.34
52 Wk Low/High 60.27 / 124.22
Volume 863.43K
Avg Volume 957.10K
Exchange NASDAQ
Shares Outstanding 106.54M
Market Cap 7.46B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam Initiates Dosing In PNH Patients In Phase 1/2 Clinical Trial For ALN-CC5

Alnylam Initiates Dosing In PNH Patients In Phase 1/2 Clinical Trial For ALN-CC5

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it initiated the final phase (Part C) of its Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered...

Alnylam Pharmaceuticals To Present Path To "Alnylam 2020" At R&D Day

Alnylam Pharmaceuticals To Present Path To "Alnylam 2020" At R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today at a presentation in New York City will discuss pipeline progress across its three strategic therapeutic areas (STArs)...

Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)

Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Alnylam Reports Positive Phase 1 Study Results For Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) In Patients With Hemophilia A And B

Alnylam Reports Positive Phase 1 Study Results For Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) In Patients With Hemophilia A And B

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today positive results from its ongoing Phase 1 clinical study with fitusiran (fi-TOO-si-ran), the recommended...

Alnylam Reports That ALN-CC5 Achieves Up To 99 Percent Knockdown Of Serum C5 And Up To 98 Percent Inhibition Of Serum Hemolytic Activity With Durability Supportive Of Once Monthly And Possibly Once Quarterly Subcutaneous Dose Regimen

Alnylam Reports That ALN-CC5 Achieves Up To 99 Percent Knockdown Of Serum C5 And Up To 98 Percent Inhibition Of Serum Hemolytic Activity With Durability Supportive Of Once Monthly And Possibly Once Quarterly Subcutaneous Dose Regimen

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today positive interim results from its ongoing Phase 1/2 clinical study with ALN-CC5, an investigational RNAi therapeutic...

3 Drugs Stocks Moving The Industry Upward

3 Drugs Stocks Moving The Industry Upward

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Alnylam To Webcast R&D Day

Alnylam To Webcast R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day live on the Investors section of the company's website, www.

Alnylam To Webcast Presentations At Upcoming December Investor Conferences

Alnylam To Webcast Presentations At Upcoming December Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 27 th Annual Piper Jaffray Healthcare Conference on...

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen

Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and  The Medicines Company (Nasdaq:MDCO), a leading biopharmaceutical development and cardiovascular product company, today...

Alnylam (ALNY) Stock Climbs Following Earnings Release

Alnylam (ALNY) Stock Climbs Following Earnings Release

Alnylam (ALNY) shares rose today after the company reported mixed third quarter results.

3 Drugs Stocks Driving The Industry Higher

3 Drugs Stocks Driving The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results And Highlights From Recent Period

Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results And Highlights From Recent Period

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced consolidated financial results for the third quarter 2015 and highlighted recent progress in its advancing pipeline.

Alnylam To Present New Clinical Results With Investigational RNAi Therapeutics At 57th Annual Meeting Of The American Society Of Hematology (ASH)

Alnylam To Present New Clinical Results With Investigational RNAi Therapeutics At 57th Annual Meeting Of The American Society Of Hematology (ASH)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Alnylam scientists and collaborators will present new results from ongoing clinical studies with two of its...

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Alnylam Reports Positive Results From Ongoing Phase 2 Open-Label Extension (OLE) Studies For Patisiran And Revusiran, In Development For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Alnylam Reports Positive Results From Ongoing Phase 2 Open-Label Extension (OLE) Studies For Patisiran And Revusiran, In Development For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational...

Alnylam To Webcast Presentations At Upcoming November Conferences

Alnylam To Webcast Presentations At Upcoming November Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 24th Annual Credit Suisse Healthcare Conference on Tuesday,...

Alnylam To Webcast Conference Call Discussing Third Quarter 2015 Financial Results

Alnylam To Webcast Conference Call Discussing Third Quarter 2015 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2015 on Monday, November 9, 2015,...

Alnylam To Report New Clinical Results With Investigational RNAi Therapeutics For The Treatment Of Transthyretin-Mediated Amyloidosis At The First European Congress On Hereditary ATTR Amyloidosis

Alnylam To Report New Clinical Results With Investigational RNAi Therapeutics For The Treatment Of Transthyretin-Mediated Amyloidosis At The First European Congress On Hereditary ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Alnylam scientists and collaborators will present results from ongoing Phase 2 open-label extension (OLE) studies...

Alnylam Demonstrates Continued Commitment To Transthyretin-Mediated Amyloidosis Patients With Advancement Of ALN-TTRsc02, An Investigational RNAi Therapeutic With Potential For Low Volume, Once Quarterly, Subcutaneous Dose Regimen

Alnylam Demonstrates Continued Commitment To Transthyretin-Mediated Amyloidosis Patients With Advancement Of ALN-TTRsc02, An Investigational RNAi Therapeutic With Potential For Low Volume, Once Quarterly, Subcutaneous Dose Regimen

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it presented key pre-clinical data and provided program guidance for ALN-TTRsc02, an investigational RNAi...

Alnylam Advances New Innovations In RNAi Therapeutics

Alnylam Advances New Innovations In RNAi Therapeutics

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today advancement of innovations in RNAi therapeutics with presentation of scientific data on two new platform technologies.

Alnylam Initiates Phase 1 Open Label Extension (OLE) Study With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders

Alnylam Initiates Phase 1 Open Label Extension (OLE) Study With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 open-label extension (OLE) study with ALN-AT3, a subcutaneously administered,...

Alnylam Pharmaceuticals (ALNY) Marked As A Dead Cat Bounce Stock

Alnylam Pharmaceuticals (ALNY) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Alnylam And Genzyme Announce That Genzyme Opts Into ALN-AT3 Hemophilia Program For Development And Commercialization Outside Of North America And Western Europe

Alnylam And Genzyme Announce That Genzyme Opts Into ALN-AT3 Hemophilia Program For Development And Commercialization Outside Of North America And Western Europe

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), today announced that Genzyme has elected to opt into Alnylam's...

Alnylam Granted Summary Judgment By United States District Court For The District Of Massachusetts In Tuschl II Patent Inventorship Dispute

Alnylam Granted Summary Judgment By United States District Court For The District Of Massachusetts In Tuschl II Patent Inventorship Dispute

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Chief Judge Patti B.

Alnylam And Collaborators Report First-Ever Evidence That Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Monomers And Oligomers In TTR-Mediated Amyloidosis (ATTR Amyloidosis) Patients With Familial Amyloidotic Polyneuropathy (FAP)

Alnylam And Collaborators Report First-Ever Evidence That Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Monomers And Oligomers In TTR-Mediated Amyloidosis (ATTR Amyloidosis) Patients With Familial Amyloidotic Polyneuropathy (FAP)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators announced today new results from the company's ongoing Phase 2 open-label extension (OLE) study of patisiran, an...

Alnylam Pharmaceuticals Becomes Oversold

Alnylam Pharmaceuticals Becomes Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Today's Water-Logged And Getting Wetter Stock: Alnylam Pharmaceuticals (ALNY)

Today's Water-Logged And Getting Wetter Stock: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Alnylam Reports Positive Initial Clinical Results For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias

Alnylam Reports Positive Initial Clinical Results For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today initial positive results from its ongoing Phase 1 clinical trial with ALN-AS1, an investigational RNAi therapeutic...

Alnylam To Webcast Presentations At Upcoming September Conferences

Alnylam To Webcast Presentations At Upcoming September Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Friday, September...